Kidney biopsy in lupus nephritis: Look before you leap

Nephrology Dialysis Transplantation

Volumn 21, Issue 7, 2006, Pages 1749-1752

  Bihl, Geoffrey R ^a   Petri, Michelle ^b   Fine, Derek M ^b  

^a Winelands Kidney and Dialysis Center   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Focal glomerular pathology; Safety; Specific diagnosis; Treatment recommendation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HEPARIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; SHORT ACTING DRUG; WARFARIN;

BLEEDING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; GONAD DYSFUNCTION; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY DISEASE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REMISSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; TUBERCULOSIS;

BIOPSY; HUMANS; KIDNEY; KIDNEY DISEASES; LUPUS NEPHRITIS; PROGNOSIS; SAFETY;

EID: 33745612708     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl159     Document Type: Note

References (26)

1. McGill PE, Oyoo GO. Rheumatic disorders in sub-Saharan Africa. East Afr Med J 2002; 79: 214-216
2. Bihl G. Lupus nephritis: Current issues. Spec For 2004; 8: 55-66
3. Alarcon GS, Friedman AW, Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. nurture. Lupus 1999; 8: 197-209
4. Nossent JC, Henzen-Logmans SC, Vroom TM, Huysen V, Berden JH, Swaak AJ. Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int 1991; 11: 77-82
5. Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J. Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med 1989; 73: 1125-1133
6. Ling BN, Bourke E, Campbell WG,Jr, Delaney VB. Naproxen-induced nephropathy in systemic lupus. Nephron 1990; 54: 249-255
7. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
8. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens 2005; 14: 1-8
9. Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus 1998; 7: 611-617
10. Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 1988; 8: 85-89
11. Mok CC, Wong RW, Lai KN. Treatment of severe proliferative lupus nephritis: The current state. Ann Rheum Dis 2003; 62: 799-804
12. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131
13. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong - Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
14. Ginzler EM, Aranow C. Mycophenolate mofetil in lupus nephritis. Lupus 2005; 14: 59-64
15. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
16. Gourley MF, Austin HA,3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557
17. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257
18. Tikly M, Burgin S, Mohanlal P, Bellingan A, George J. Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations. Clin Rheumatol 1996; 15: 143-147
19. Dessein PH, Gledhill RF, Rossouw DS. Systemic lupus erythematosus in black South Africans. S Afr Med J 1988; 74: 387-389
20. Mok MY, Lo Y, Chan TM, Wong WS, Lau CS. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy, J Rheumatol 2005; 32: 609-615
21. Mody GM, Parag KB, Nathoo BC, Pudifin DJ, Duursma J, Seedat YK. High mortality with systemic lupus erythematosus in hospitalized African blacks. Br J Rheumatol 1994; 33: 1151-1153
22. Balow JE, Austin HA,3rd. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003; 23: 386-391
23. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998; 31: 681-686
24. Austin HA, Illei GG. Membranous lupus nephritis. Lupus 2005; 14: 65-71
25. Spetie DN, Tang Y, Rovin BH et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66: 2411-2415
26. Hebert LA, Dillon JJ, Middendorf DF, Lewis EJ, Peter JB. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995; 26: 432-438